• Consider Liquidia (LQDA) only as a high-risk, event-driven idea: the speaker sees potential for a return to $100 if it wins its appeal, but that outcome is uncertain.
• The clearest bearish theme is semiconductor supply risk: the speaker was short Micron (MU) and ASML, and flagged SanDisk as vulnerable if Asian supply rises; no price targets were provided.
• The speaker also favored shorting technology over healthcare, citing potential supply pressure and CPU weakness that could affect Dell (DELL), Intel (INTC), and AMD (AMD), though this was a developing thesis rather than a defined trade.
• MongoDB (MDB) was a tentative hold, with a possible re-entry below $351; the speaker expressed hesitation about software stocks and did not favor a larger position.

Micron Technology (MU)

• The speaker initially said Micron had reported good earnings and guidance and would “probably continue grinding up.” Later, however, he said he was short Micron.
  • He cited a TrendForce report on DRAM and the possibility that increased Chinese supply could pressure Micron and the broader market.
  • He also noted that Micron’s next quarterly report was due the following week.
• The speaker said another trader had bought and sold Micron more than once; that trader was reportedly out of the position at the time.

Takeaways

• The discussion presents a change in stance: positive reaction to earnings and guidance, followed by a bearish short thesis based on prospective supply competition.
• The $100 price level was mentioned for Liquidia, not Micron. No Micron price target was given.

ASML Holding (ASML)

• The speaker discussed shorting ASML, arguing that Chinese supply could put pressure on the company and related semiconductor stocks.
• He also called ASML “the best company to ever exist,” apparently in a joking or ironic exchange, before reiterating the bearish supply concern.

Takeaways

• The short thesis is based on potential competition from China, not criticism of ASML’s business quality.
• This is a strongly debated trade in the transcript: the speaker acknowledged the company’s quality while favoring a short based on supply risk.

SanDisk

• The speaker said SanDisk could fall if Asian suppliers significantly increase supply, alongside Micron and the broader market.

Takeaways

• The bearish view is conditional on a supply increase. No timing or price target was mentioned.

Semiconductor and Computer Hardware Stocks

• The speaker described a possible “perfect storm” for technology stocks, citing:
  • Potential semiconductor supply increases from China.
  • Signals of CPU weakness.
  • A weak macroeconomic backdrop and high deficits.
• Dell (DELL), Intel (INTC), and AMD (AMD) were named as companies that could be affected by CPU weakness.
• The speaker also noted a report that wafer-foundry prices could rise 3% to 6%, but did not say this was a major move.
• He said he was considering shorting more broadly and preferred healthcare over technology at that moment. He also said he was shorting “quantum,” without naming specific companies.

Takeaways

• The overall technology and semiconductor tone was bearish, but much of the thesis was expressed as a developing concern or gut feeling rather than a detailed forecast.
• The supply, CPU-demand, and macroeconomic concerns are distinct risks; the transcript provides no specific price targets or trade sizes for these names.

Liquidia Corporation (LQDA)

• The speaker said Liquidia was down another 20% and that he believed it could return to $100 if it wins its appeal.
• He described the stock as already depressed before the latest decline.

Takeaways

• The bullish case is explicitly conditional on winning the appeal.
• The appeal is the key risk mentioned in the discussion; the $100 level was presented as a possible outcome, not a guaranteed target.

MongoDB (MDB)

• The speaker questioned why someone was holding MongoDB, saying he was unsure about trading software “especially right now.”
• He then agreed to hold the position, said “we still like it,” and suggested buying back in below a prior sell price of $351. He also said he did not need a larger position.

Takeaways

• The view was mixed: some hesitation about software stocks, but continued willingness to hold MongoDB.
• $351 was discussed in the context of a possible re-entry, not as a formal price target.

Accenture (ACN)

• The speaker described Accenture’s reported numbers as “big” and noted that many investors had been short.

Takeaways

• The comments suggest a potentially unfavorable setup for crowded short positions after strong results.
• No explicit recommendation or price target was given.

Nektar Therapeutics (NKTR)

• The speaker said Nektar’s data “didn’t look good” or at least did not please the market.
• He then said he had shorted it and used the phrase “go all in,” in a casual, joking exchange.

Takeaways

• The expressed view was bearish, tied to the market’s reaction to the data.
• The transcript does not provide details about the data, a price target, or a clearly stated position size. The “all in” remark should not be treated as a measured risk plan.

Moderna (MRNA)

• The speaker said he was short Moderna and identified it as his largest short.
• He mentioned an average price of $191 and said he had covered some of the short earlier before shorting again.
• He also cited Moderna’s cash position and commented that COVID demand had faded. He said the stock had not had important news since 2024, according to his view.

Takeaways

• The speaker’s position was bearish, but he acknowledged that Moderna had rallied and that he had been fortunate to avoid part of that move.
• The $191 figure was described as his average, not a price target. The transcript underscores the risk of being short a stock that can rally.

Kodiak Sciences (KOD)

• The speaker described Kodiak as an upcoming binary event, with uncertainty over whether news would arrive that day or by the end of the third quarter, which he said was the following week.
• He said he had a short position, but “not that big,” and noted that the company did not have much cash.
• He characterized the setup as potentially “all or nothing.”

Takeaways

• This is a high-uncertainty, event-driven situation. The speaker’s small position and the binary-event framing indicate substantial outcome risk.
• No specific event date or price target was provided.

IBA

• The speaker said he was short a small amount of IBA.
• His stated rationale was that others had previously tested the same mechanism in the disease and had not succeeded.

Takeaways

• The short thesis rests on prior failed attempts with the same mechanism.
• The transcript does not identify the relevant drug or trial, so the thesis is difficult to evaluate from this discussion alone.

SELLAS Life Sciences (SLS)

• The speaker said he was short SLS and thought it was “worthless.”
• He also made a joking remark that another company could take over its ticker if it disappeared.

Takeaways

• The expressed view was strongly bearish, but no supporting financial or clinical details were discussed.
• The ticker-related remark was clearly banter, not an investment catalyst.

Bitcoin (BTC)

• The speaker discussed shorting Bitcoin using perpetual contracts and mentioned considering 40× leverage.
• He noted that transaction costs would require the position to move enough to overcome costs on both entry and exit.
• He also said Bitcoin could “run my short over,” acknowledging the risk of a sharp move against the position.

Takeaways

• This was a speculative, leveraged short discussion—not a long-term Bitcoin thesis.
• The speaker explicitly highlighted the risk of being squeezed by a price rise. High leverage can magnify losses as well as gains.

Akamai Technologies (AKAM) and Anthropic

• The speaker reacted to “Akamai and Anthropic” news, saying the move was quick and that some puts were his.
• The transcript does not make clear whether the puts were on Akamai or which specific news drove the price move. Anthropic was mentioned as a private company, not as a publicly traded stock.

Takeaways

• The speaker appeared to have a put position connected to the news-driven move, but the precise trade and thesis are unclear.
• No price target or timing was provided.

Costco (COST)

• The speaker said another trader was short Costco and called it a “no brainer,” without providing supporting details.

Takeaways

• This was a brief, second-hand bearish comment; the transcript does not establish the speaker’s own position or explain the short thesis.

Unity Software (U)

• The speaker said Unity was being pressured and mentioned a theory that Meta might be competing with it.
• He added that he did not know whether the competition mattered much.

Takeaways

• The potential competitive threat was presented as speculation, not a firm bearish conclusion.
• The speaker expressed uncertainty about how material the threat was.

Corteva (CTVA)

• Corteva was mentioned in connection with a spinoff.

Takeaways

• No valuation view, recommendation, or specific implications of the spinoff were discussed.

Regeneron Pharmaceuticals (REGN)

• The speaker briefly said “bullish Regeneron” while discussing a list of upcoming events, but did not explain the catalyst.

Takeaways

• The mention indicates a positive view, but the transcript gives no supporting rationale, timeline, or price target.

Spruce Biosciences, Replimune, and uniQure

• The speaker said “we made money in Spruce,” while acknowledging that someone who bought at the top may have lost money.
• He also said “Repta” would still go to several hundred dollars and mentioned “Unicure.” The exact company names in this part of the transcript are unclear.

Takeaways

• The Spruce comment describes a past profitable trade, not necessarily a current recommendation.
• The apparent Replimune/uniQure references are too unclear to support a reliable investment conclusion or price target.

Rose AI

• The speaker described Rose AI as an IPO by a company he had not heard of, jokingly calling it a “fake AI company,” while also speculating that it might be a cloud company.

Takeaways

• The comments express skepticism and uncertainty, not a substantiated short thesis.
• No ticker, financial information, or trade recommendation was provided.

Healthcare and Biopharma Themes

• The speaker said he would rather be in healthcare than technology at that moment, given his concerns about the technology rally and semiconductor supply.
• He noted that drug products eventually face loss of exclusivity and generic competition, citing Dupixent as an example of generics that he said were coming.
• He also mentioned Pfizer in connection with the decline in COVID demand.

Takeaways

• The discussion expressed a relative preference for healthcare over technology, not a broad endorsement of every healthcare stock.
• The speaker highlighted patent expiry and fading COVID-related demand as risks for biopharma businesses.

Other Brief Mentions

• Twist Bioscience (TWST): The speaker noted that the stock had risen sharply, without giving a thesis.
• Viking Therapeutics (VKTX): He observed that the stock had rallied; no recommendation was stated.
• Spruce Biosciences: Mentioned above as a past profitable trade.
• Broadcom (AVGO): The speaker said they did not have a position.
• Meta Platforms (META): The speaker said he was not short and had no firm view.
• Replimune (REPL), if “Repta” refers to that company: A very bullish price claim was made, but the transcript is unclear.
• Meme coins such as Pepe, Dog, Cat, and Squirrel coins: Mentioned jokingly, with no investment thesis.